Lisbon 2017 Delegate Registration Programme Exhibition Virtual Exhibition Satellites OneWorld Travel Discount
escrs app advert

Visual outcome and corneal and ocular surface changes with Rose K2 XL semi-scleral contact lenses in advanced keratoconus

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Quality of Vision/Miscellaneous

Venue: Poster Village: Pod 3

First Author: : R.Sinha INDIA

Co Author(s): :    S. Kain   M. Chaniyara   T. Agarwal   N. Sharma   J. Titiyal  

Abstract Details

Purpose:

To perform a study evaluating visual outcome with semi-scleral contact lenses and to assess the ocular surface and corneal response to these lenses in advanced keratoconus.

Setting:

Dr Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi.

Methods:

Thirty eyes with advanced primary keratoconus were fitted with RoseK2XL semiscleral. Patients of 17 to 40 years of age with Kmax value of more than 60diopters were included. The parameters evaluated were uncorrected visual acuity (UCVA), best spectacle corrected visual acuity (BSCVA), bcst contact lens corrected visual acuity (BCLCVA), corneal topography by orbscan II, pachymetry, glare acuity, contrast sensitivity, schirmer’s test, tear breakup time (TBUT), specular count and confocal microscopy.

Results:

The BSCVA was 0.199±0.059 in snellen’s decimals which improved significantly with RoseK2XL contact lens to 0.70±0.16. There was no significant change in keratometry, corneal thickness and endothelial cell count at 6 months. The contrast sensitivity increased significantly from 0.75±0.32 to 1.52±0.14. Glare acuity increased significantly from 0.75±0.32 to 1.52±0.14. There was no significant change in the values of schirmer’s, TBUT and keratocyte count per mm2 at six months.

Conclusions:

Rose K2XL semi scleral contact lens provides good outcome in terms of improvement in visual acuity, quality of vision and comfort in patients of advanced keratoconus without causing any significant adverse corneal and ocular surface changes.

Financial Disclosure:

NONE

Back to previous